Summit Therapeutics Investor Relations Material

Summit Therapeutics Inc., headquartered in Menlo Park, California, is a biopharmaceutical company engaged in the research and development of oncology therapies in the United States and the United Kingdom. Its lead pipeline product, ivonescimab, is a novel, bispecific antibody targeting both PD-1 and VEGF. Summit Therapeutics has also initiated two clinical trials with ivonescimab. Additionally, the company's product pipeline includes SMT-738, a novel class of precision antibiotics aimed at treating multidrug-resistant infections, including carbapenem-resistant Enterobacteriaceae infections. The company is headquartered in Menlo Park, California, and its shares are listed on the Nasdaq.